Form 4: Celldex Therapeutics CFO Acquires Stock Options

Celldex Therapeutics SVP and CFO, Samuel Bates Martin, was granted stock options for 93,000 shares of common stock.

Summary

• Samuel Bates Martin, SVP and CFO of Celldex Therapeutics, Inc., was granted an incentive stock option on June 25, 2026.
• The option allows for the purchase of 93,000 shares of common stock at an exercise price of $34.09 per share.
• The options vest over a period, with 25% vesting on June 25, 2027, and the remaining 75% vesting quarterly over the subsequent 12 quarters.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event rather than a significant financial or strategic development for the company.

Positives

• Granting of stock options to a key executive like the CFO can indicate management's commitment and alignment with shareholder interests.
• The vesting schedule over several years encourages long-term performance and retention.

Negatives

• The exercise price of $34.09 is a significant hurdle, meaning the stock price would need to increase substantially for the options to be profitable.

Risks

• The value of the stock options is entirely dependent on the future performance of Celldex Therapeutics' stock price.
• If the company's stock price does not exceed $34.09 per share, the options will expire worthless.

Future Outlook

The future outlook for the stock options is contingent on the company's stock performance exceeding the exercise price of $34.09 by the expiration date of June 25, 2036.

Industry Context

StockSavvy.ai notes that the granting of stock options to senior executives is a common practice in the biotechnology and pharmaceutical sectors to incentivize performance and align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The granting of options does not immediately dilute share count but could lead to future dilution if exercised. The alignment of executive incentives with stock performance is generally viewed positively.
• Employees: This filing pertains to executive compensation and does not directly impact other employees.
• Management: The CFO has been granted an incentive tied to the company's stock performance, aligning their financial interests with shareholders.

Next Steps

• The stock options will vest over time according to the schedule outlined.
• Samuel Bates Martin may choose to exercise the vested options if the stock price is above the exercise price.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, Stock Options, Executive Compensation, Insider Trading, SVP and CFO, Samuel Bates Martin, Equity Incentive Plan